Strategic partnerships Leverage 858 Therapeutics’ strong collaboration history and recent OpenBench collaboration to identify co-development or sponsored research opportunities with mid-to-large biotechs and contract research organizations looking to expand small molecule oncology pipelines.

Pipeline expansion Position ETX-19477 and future PARG inhibitor programs as attractive for partners seeking novel targets in cancer that are resistant to standard therapies, offering collaboration or licensing options to accelerate clinical development.

Financing signals Recent Series B funding and ongoing Phase 1/2 activities signal momentum; target investors and strategic corporate partners in oncology to explore co-investment, strategic alliances, or value-added partnerships that align with future fundraising milestones.

Geographic access San Diego and New York operations provide access to diverse talent pools and regional biotech ecosystems; propose site-symmetric studies or joint opportunities with regional CROs and academic collaborators to de-risk and accelerate programs.

Clinical readiness With initial data from ETX-19477 due at major meetings (ASCO, AACR) and a track record in epigenetics, genomics, and innate immunity, offer early engagement for advisory boards, feasibility studies, or investigator-initiated trials to extend clinical development reach.